Viral Vector Core

病毒载体核心

基本信息

批准号：
10248346
负责人：
JOEL R CHAMBERLAIN
金额：
$ 23.72万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-07 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10248346
关键词：
Animal Model Animals Antibodies Basic Science Biology Biotechnology Canis familiaris Cardiac Myocytes Cell Culture Techniques Cell Line Cells Centrifugation Collaborations Complementary DNA Consult Consumption Cytokeratin-8 Staining Method Cytomegalovirus Doctor of Philosophy Dystrophin Family suidae Funding Gene Transduction Agent Gene Transfer Genes Hand High Pressure Liquid Chromatography Human Resources Immune Sera Laboratories Learning Lentivirus Vector Methods Muscle Muscular Dystrophies Myoblasts Myopathy Plasmid Cloning Vector Plasmids Preparation Procedures Production Protein Isoforms Protocols documentation RNAi vector Reagent Recombinants Regulator Genes Research Research Personnel Resources Retroviral Vector Role Roller Bottle Serotyping Services Technology Testing Time Training Transfection Translational Research Utrophin Vertebral column Viral Viral Vector Visit Work adeno-associated viral vector base cost gene therapy improved induced pluripotent stem cell interest member mouse model operation outreach research and development research study stem cells therapeutic development vector web site

项目摘要

VIRAL VECTOR CORE: Summary/Abstract This Viral Vector Core has been in operation for nearly 12 years, and its main role has been to support the Wellstone Center in Seattle as a Scientific Research Resource Core. The Core also offers support to non-Center members on a recharge basis. The Core provides high quality preparations of viral and plasmid vectors to facilitate research related to the muscular dystrophies. Services offered by the Core include providing consulting, reagents and training related to vector production. This includes production of adeno-associated and lentiviral vectors and muscular dystrophy related reagents (cell lines, vector backbones, protocols, antibodies etc) for members of this Center as well as laboratories in the US and across the World to support their efforts related to gene therapy for the muscular dystrophies. The Principle Investigator of the Vector Core is now Dr. Joel Chamberlain, who has worked closely with Core personnel on AAV and retroviral vectors for more than 10 years. The manager of the Core is Dr. James Allen. Dr. Allen, in conjunction with the Chamberlain, Russel, Odom and Hauschka labs has established protocols for the production of adeno-associated viral vectors, particularly AAV6 and 9, but also several other pseudotyped vectors including AAV1, 5, 7,8 and 8i, and VSVG-lentiviral vectors. For many years such vectors and associated reagents have been supplied by us to laboratories around the world as part of collaborations, and for the past 3.5 years (and a previous 5 year period) these reagents have been provided via the Wellstone Center Vector Core lab. We also have numerous dystrophin and utrophin cDNAs and antibodies that will be made available via this Core lab, as well as DM1, DUX4 and associated RNAi vectors. We will provide high quality, high titer preparations of adeno-associated viral (AAV) vectors based primarily on AAV serotypes 6 & 9, but also for AAV 1, 2, 8 and emerging new and modified serotypes. These recombinant AAV (rAAV) vectors will be provided to members of the Wellstone Center using funds from this Core, and to other muscular dystrophy researchers on a recharge basis to cover costs. We also have numerous muscle disease related cDNAs and antibodies that will be made available via this Core lab for all members of our Center. Training will allow investigators to apply methods for production and purification of viral vectors (AAV and lentiviral) in their own labs as desired, and will be advertised via the Center Web site. Consulting will be available to guide the use of the AAV and lentiviral vectors. Finally, we will provide reagents (such as vector backbones, plasmids, antibodies and protocols) that have been developed by members of this Wellstone Center to outside labs.

病毒载体核心：总结/摘要这个病毒载体核心已经运行了近12年，其主要作用是支持西雅图 Wellstone 中心作为科学研究资源核心。核心还提供支持非中心会员按充值方式。 The Core 提供高质量的病毒制剂和质粒载体促进与肌营养不良症相关的研究。核心提供的服务包括提供与载体生产相关的咨询、试剂和培训。这包括生产腺相关和慢病毒载体以及肌营养不良症相关试剂（细胞系、载体为该中心的成员以及美国和美国的实验室提供骨干网、协议、抗体等）世界各地支持他们与肌肉营养不良症基因治疗相关的努力。这 Vector Core 的首席研究员现在是 Joel Chamberlain 博士，他曾与核心人员从事AAV和逆转录病毒载体研究10余年。核心经理是Dr. 詹姆斯·艾伦.艾伦博士与张伯伦、拉塞尔、奥多姆和豪施卡实验室合作，建立了腺相关病毒载体的生产方案，特别是 AAV6 和 9，但是还有其他几种假型载体，包括 AAV1、5、7,8 和 8i，以及 VSVG 慢病毒载体。为了多年来，我们已向世界各地的实验室提供此类载体和相关试剂。作为合作的一部分，在过去 3.5 年（以及之前的 5 年期间）这些试剂由 Wellstone Center Vector Core 实验室提供。我们还有大量的肌营养不良蛋白和 utropin cDNA 和抗体将通过该核心实验室提供，以及 DM1、DUX4 和相关的 RNAi 载体。我们将提供高质量、高滴度的腺相关病毒制剂 (AAV) 载体主要基于 AAV 血清型 6 和 9，但也适用于 AAV 1、2、8 和新兴的新血清型和修饰的血清型。这些重组 AAV (rAAV) 载体将提供给 Wellstone 中心使用该核心的资金以及其他肌肉营养不良研究人员的资金充值基础上支付费用。我们还有大量肌肉疾病相关的 cDNA 和抗体这将通过这个核心实验室提供给我们中心的所有成员。培训将使调查人员能够在自己的实验室中应用病毒载体（AAV 和慢病毒）的生产和纯化方法需要，并将通过中心网站进行广告宣传。将提供咨询来指导使用 AAV 和慢病毒载体。最后，我们将提供试剂（如载体骨架、质粒、 Wellstone 中心成员向外部开发的抗体和方案）实验室。